托吡酯与纳曲酮治疗酒精使用障碍:基因型分层双盲随机对照试验
该12周双盲安慰剂对照多中心基因型分层随机试验纳入147例酒精使用障碍患者,比较托吡酯与纳曲酮疗效。主要结局每周重度饮酒天数呈接近显著的时间×治疗交互;每周每饮酒日标准饮酒量交互显著 favoring 托吡酯,BMI、渴求及γ-谷氨酰转移酶下降托吡酯优于纳曲酮。两种基因多态性均未影响治疗反应。
要点
- 每周每饮酒日标准饮酒量时间×治疗交互显著,托吡酯优于纳曲酮。
- BMI、渴求及γ-谷氨酰转移酶下降托吡酯优于纳曲酮。
- 托吡酯与纳曲酮因副作用退出率分别为8%和5%。
核心结论
- 托吡酯在减少重度饮酒方面至少与一线药物纳曲酮同样有效和安全,且在改善部分临床结局方面优于纳曲酮。
- rs2832407和rs1799971多态性分别对托吡酯和纳曲酮治疗反应均无影响。
研究设计与样本
- 12周双盲安慰剂对照随机多中心基因型分层临床试验,比较托吡酯与纳曲酮治疗酒精使用障碍。
- 147例酒精使用障碍患者随机分配至托吡酯或纳曲酮,按rs2832407(CC和AC/AA基因型)及rs1799971(AA和AG/GG基因型)分层。
- 预设主要结局为每周重度饮酒天数;预设次要结局包括每周每饮酒日标准饮酒量、体重指数、渴求、肝损伤标志物、情绪及不良事件。
主要发现
- 每周重度饮酒天数的时间×治疗交互接近显著。
- 每周每饮酒日标准饮酒量的时间×治疗交互显著, favoring 托吡酯。
- 体重指数、渴求及γ-谷氨酰转移酶水平的时间×治疗效应显著,托吡酯组下降大于纳曲酮组。
- 因副作用退出者托吡酯组为8%,纳曲酮组为5%。
- 两种基因多态性均未显示对治疗反应的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There have been no well-controlled and well-powered comparative trials of topiramate with other pharmacotherapies for alcohol use disorder (AUD), such as naltrexone. Moreover, the literature is mixed on the effects of two polymorphisms-rs2832407 (in GRIK1) and rs1799971 (in OPRM1)-on response to topiramate and naltrexone, respectively. The authors sought to examine the comparative effectiveness of topiramate and naltrexone in improving outcomes in AUD and to examine the role of the rs2832407 and rs1799971 polymorphisms, respectively, on response to these medications. METHODS: In a 12-week, double-blind, placebo-controlled, randomized, multisite, genotype-stratified (rs2832407 and rs1799971) clinical trial comparing topiramate and naltrexone in treating AUD, 147 patients with AUD were randomly assigned to treatment with topiramate or naltrexone, stratified by genotype (rs2832407*CC and *AC/AA genotypes and rs1799971*AA and *AG/GG genotypes). The predefined primary outcome was number of heavy drinking days per week. Predefined secondary outcomes included standard drinks per drinking day per week, body mass index (BMI), craving, markers of liver injury, mood, and adverse events. RESULTS: For the number of heavy drinking days per week, there was a near-significant time-by-treatment interaction. For the number of standard drinks per drinking day per week, there was a significant time-by-treatment interaction, which favored topiramate. There were significant time-by-treatment effects, with greater reductions observed with topiramate than naltrexone for BMI, craving, and gamma-glutamyltransferase level. Withdrawal due to side effects occurred in 8% and 5% of the topiramate and naltrexone groups, respectively. Neither polymorphism showed an effect on treatment response. CONCLUSIONS: Topiramate is at least as effective and safe as the first-line medication, naltrexone, in reducing heavy alcohol consumption, and superior in reducing some clinical outcomes. Neither rs2832407 nor rs1799971 had effects on topiramate and naltrexone treatments, respectively.
引用
- Morley KC, Kranzler HR, Luquin N, et al. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2024. PMID: 38706338. doi:10.1176/appi.ajp.20230666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。